Three months ago AIAI was just a 15c stock, and even now market cap is low at $94M. But it has certainly done well, up 242% this year. So far, though, it looks like its AI symbol is the best feature. It has minimal cash and minimal reported revenue. Cash flow is negative. It surged yesterday on news of a 'pilot' program with a 'top five' pharma company. The program hopes to unlock insights into the development of new therapies. Details were light. Insiders own 17% and have been net buyers in the last six months. It has not had an update since August. Simply put, its aim is to use AI to improve the outcome of clinical health trials, where there is an 88% failure rate for a multitude of reasons. But there are other, larger companies doing this, and of course pharma companies themselves have an in-house incentive to improve outcomes. The company is interesting, no doubt, but we just don't have much to 'analyse' here.
5i Research Answer: